These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18463034)

  • 1. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus.
    Sheffield CA; Kane MP; Busch RS; Bakst G; Abelseth JM; Hamilton RA
    Endocr Pract; 2008 Apr; 14(3):285-92. PubMed ID: 18463034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.
    Yoon NM; Cavaghan MK; Brunelle RL; Roach P
    Clin Ther; 2009 Jul; 31(7):1511-23. PubMed ID: 19695400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
    Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.
    Tzefos M; Olin JL
    Ann Pharmacother; 2010; 44(7-8):1294-300. PubMed ID: 20530705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
    Zinman B; Hoogwerf BJ; Durán García S; Milton DR; Giaconia JM; Kim DD; Trautmann ME; Brodows RG
    Ann Intern Med; 2007 Apr; 146(7):477-85. PubMed ID: 17404349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.
    Abdul-Ghani M; Migahid O; Megahed A; DeFronzo RA; Zirie M; Jayyousi A
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2162-2170. PubMed ID: 28324038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Summaries for patients. Exenatide or insulin glargine for suboptimally controlled diabetes?
    Ann Intern Med; 2005 Oct; 143(8):I30. PubMed ID: 16230718
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
    Levin PA; Mersey JH; Zhou S; Bromberger LA
    Endocr Pract; 2012; 18(1):17-25. PubMed ID: 21742605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managed care perspective on three new agents for type 2 diabetes.
    VanDeKoppel S; Choe HM; Sweet BV
    J Manag Care Pharm; 2008 May; 14(4):363-80. PubMed ID: 18500914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
    Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
    Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Summaries for patients. Exenatide therapy for type 2 diabetes.
    Ann Intern Med; 2007 Apr; 146(7):I18. PubMed ID: 17404346
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
    Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
    Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
    Yuan GH; Song WL; Huang YY; Guo XH; Gao Y
    Chin Med J (Engl); 2012 Aug; 125(15):2677-81. PubMed ID: 22931974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
    Ridge T; Moretto T; MacConell L; Pencek R; Han J; Schulteis C; Porter L
    Diabetes Obes Metab; 2012 Dec; 14(12):1097-103. PubMed ID: 22734440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
    Blonde L; Klein EJ; Han J; Zhang B; Mac SM; Poon TH; Taylor KL; Trautmann ME; Kim DD; Kendall DM
    Diabetes Obes Metab; 2006 Jul; 8(4):436-47. PubMed ID: 16776751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.
    Pawaskar M; Li Q; Hoogwerf BJ; Reynolds MW; Lee LJ; Fonseca V
    Endocr Pract; 2012; 18(5):700-11. PubMed ID: 22982784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.
    Pencek R; Brunell SC; Li Y; Hoogwerf BJ; Malone J
    Endocr Pract; 2012; 18(2):227-37. PubMed ID: 22446132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.